Comparison of EGFR Signaling Pathway Somatic DNA Mutations Derived From Peripheral Blood and Corresponding Tumor Tissue of Patients with Advanced Non-Small-Cell Lung Cancer Using Liquidchip Technology
- 28 August 2013
- journal article
- research article
- Published by Elsevier BV in The Journal of Molecular Diagnostics
- Vol. 15 (6), 819-826
- https://doi.org/10.1016/j.jmoldx.2013.06.006
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 TrialThe Oncologist, 2012
- Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 2012
- Genetic Testing for Lung Cancer: Reflex Versus Clinical SelectionJournal of Clinical Oncology, 2011
- Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancerCancer Science, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- Molecular Predictors of Outcome With Gefitinib in a Phase III Placebo-Controlled Study in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Changing Epidemiology of Small-Cell Lung Cancer in the United States Over the Last 30 Years: Analysis of the Surveillance, Epidemiologic, and End Results DatabaseJournal of Clinical Oncology, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeThe New England Journal of Medicine, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004